Skip to main content
SpringerLink
Log in

Co-Dergocrin (Dihydroergotoxin)

  • Chapter
Neuro-Psychopharmaka

Zusammenfassung

Co-Dergocrin-Mesilat ist ein Mutterkornalkaloid, das im Verhältnis 3:3:2:1 aus den Methansulfonaten der vier dehydrierten Ergopeptidderivate: Dihydrocornin, Dihy-droergocristin, Dihydro-Alpha-ergocryptin, Dihydro-Beta-ergocryptin zusammengesetzt ist. Co-Dergocrin zeigt, wie die meisten Mutterkornalkaloide, ein breites Spektrum pharmakologischer Wirkungen, die nicht auf einen einzigen grundlegenden Mechanismus auf zellulärer oder molekularer Ebene zurückzuführen sind. Co-Dergocrin besitzt wie die Einzelkomponenten eine blockierende Wirkung auf Alpha-Adrenorezeptoren.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Aellig WH, Nuesch E (1977) Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration in man. Int J Clin Pharmacol 15: 106–112

    CAS  Google Scholar 

  • Arrigo A, Braun P, Kauchtschischwili GM (1973) Influence of treatment on symptomatology and correlated electroencephalographic (EEG) changes in the aged. Clin Ther Res 15: 417–426

    CAS  Google Scholar 

  • Baldy-Moulinier M, Dapres G, Passouant P (1969) Organization of sleeping and waking in the cat during the 24 hours: pharmacological changes. Electroencephalogr Clin Neurophysiol 27: 105

    PubMed  CAS  Google Scholar 

  • Banen DM (1972) An ergot preparation (Hydergine) for relief of symptoms of cerebrovascular insuffiency. J Am Geriatr Soc 20: 22–24

    PubMed  CAS  Google Scholar 

  • Bargheon J (1973) Double-blind study of hydergine in geriatric patients. Nouv Presse Med 2: 2053–2055

    PubMed  CAS  Google Scholar 

  • Barnhard PJ (1961) Centr Mr J Med 7: 355–360 (zit. nach Weil 1988)

    Google Scholar 

  • Bazo AJ (1973) An ergot alkaloid preparation (Hydergine) versus papaverine in treating common complaints of the aged: double-blind study. J Am Geriat Soc 21: 63–71

    PubMed  CAS  Google Scholar 

  • Berde B (1972) Some new vascular and biochemical aspects of the mechanism of action of ergot compounds. Headache 11: 139–147

    Article  PubMed  CAS  Google Scholar 

  • Bertoni-Freddari C, Giuli C, Pieri C, Paci D (1986) Quantitative investigation of the morphological plasticity of synaptic junctions in rat dentate gyms during aging. Brain Res 366: 187–192

    Article  PubMed  CAS  Google Scholar 

  • Bertoni-Freddari C, Giuli C, Pieri C et al. (1987) The effect of chronic Hydergine treatment on the plasticity of synaptic junctions in the denate gyms of aged rats. J Gerontol 42: 482–486

    Article  PubMed  CAS  Google Scholar 

  • Biel ML, Seus R, Struppler A (1976) Medikamentöse Therapie des hirnorganischen Psychosyndroms im Alter. Med Klin 71: 2177–2189

    PubMed  CAS  Google Scholar 

  • Bluntschli HJ, Goetz RH (1947) The effect of a new sympathicolytic drug (Dihydroergocornine) on the blood-pressure with special reference to hypertension. S Mr Med J 11: 382

    Google Scholar 

  • Bock KD, Welzel D, Dennler HJ (1982) Co-Dergocrinemesylat bei älteren Hypertonikern (therapeutische Mitteilung). Münch Med Wochenschr 124: 1095–1098

    CAS  Google Scholar 

  • Breeze RW, Cox S, Rodgers-Cox J (1988) Changes in P-300 latency as a result of co-dergocrine mesylate therapy in patients with senile dementia. Int J Geriatr Psychiat 3: 263–266

    Article  Google Scholar 

  • Cerlelti A, Emmeneggerh, Enz A, Iwangoff P, Meier-Ruge W (1973) Effects of ergot DH-alkaloids on the metabolism and function of the brain. An approach based on studies with DH-Ergonine. In: Genazzani E, Herken H (eds) Centr Nerv Stud on Metab Regul and Funct. Springer, Berlin Heidelberg New York, pp 201–212

    Google Scholar 

  • Chien C, Marder SR, Van Putten T, Escobar J (1980) In: Collegium Internationale Neuropsychopharmacologicum. Prog Neuro-Psychopharmacol 1: 105–106

    Google Scholar 

  • Chierichetti S, Cucinotta D, Santini V (1985) In: Gmtz CM, Samorajski T (eds) Ageing 2000: our health care destiny, vol I. Springer, Berlin Heidelberg New York Tokyo, pp 377–393

    Chapter  Google Scholar 

  • Closse A, Frick W, Dravid A et al. (1984) Classification of drugs according to receptor profiles. Naunyn Schmiedebergs Arch Pharmacol 327: 95–101

    Article  PubMed  CAS  Google Scholar 

  • Cole JO (1980) Drug therapy of senile organic drug syndromes. Psychiat J Univ Ottawa 5: 41–52

    Google Scholar 

  • Cox JR, Pandurangi VR, Wallace MG (1978) Drugs will help if dementing patients are caught early. Mod Geriatr 8: 12, 14–15

    Google Scholar 

  • Cripps H, Dearnaley DP (1972) Vascular responses and noradrenaline overflows in the isolated blood-perfused cat spleen: some effects of cocaine, normetanephrine and a-blocking agents. J Physiol 227: 647–664

    PubMed  CAS  Google Scholar 

  • Ditch M, Kelly FJ, Resnick O (1971) An ergot preparation (Hydergine) in the treatment of cerebrovascular disorders in the geriatric patient: a double-blind study. J Am Geriatr Soc 19: 208–217

    PubMed  CAS  Google Scholar 

  • Dominiak P, Weidinger G (1983) Therapie der isolierten systolischen Hypertonie im Alter. Med Klin 78: 536–539

    Google Scholar 

  • Dravid AR, Hiestand P (1985) Deficit des activites enzymatiques cholinergiques dans les zones septo-temporales de l’hyppocampe de rat age et dans le cerveau anterieur de souris agée. Action du traitement par l’hydergine. J Pharmacol 16 [Suppl III]: 29–37

    CAS  Google Scholar 

  • Einspruch BC (1976) Helping to make the final years meaningful for the elderly residents of nursing homes. Dis Nerv Syst 37: 439–442

    PubMed  CAS  Google Scholar 

  • Emmenegger H, Meier-Ruge W (1968) The actions of Hydergine on the brain. A histochemical, circulatory and neurophysiological study. Pharmacology 1: 65–78

    Article  PubMed  CAS  Google Scholar 

  • Fanchamps A (1979) Controlled studies with dihydroergotoxine in senile cerebral insufficiency. In: Nandy K (ed) Geriatric psychopharmacology. Elsevier North-Holland, New York, pp 195–212

    Google Scholar 

  • Fanchamps A (1983) Dihydroergotoxine in senile cerebral insufficiency. In: Agnoli A, Crepaldi G, Spano PF, Trabucchi M (eds) Aging brain and ergot alkaloids. Raven Press, New York, pp 311–322 (Aging, vol 23)

    Google Scholar 

  • Flückinger E, Balthasar HU (1967) Dihydroergocristin: Unterschiedliche Wirkungen an venösem und arteriellem Gewebe. Arzneimittelforschung 17: 6–9

    Google Scholar 

  • Freis ED, Stanton JR, Wilkins RW (1948) The effects of certain dihydrogenated alkaloids of ergot in hypertensive patients. Am J Med Sci 216: 163

    Article  PubMed  CAS  Google Scholar 

  • Gaddum JA, Paasonen MKV (1955) Br J Pharmacol 10: 474–483 (zit nach WEIL 1988)

    CAS  Google Scholar 

  • Gaitz CM, Varner RV (1974) Pharmacotherapy of late life organic brain syndromes; evaluation of Hydergine (an ergot derivative) versus placebo using double-blind technique. Gerontologist 14: 44

    Article  Google Scholar 

  • Gaitz CM, Hartford JT (1979) Ergot alkaloids in treatment of geriatric patients with dementia. In: Nandy K (ed) Geriatric psychopharmacology. Elsevier North-Holland, New York, pp 213–224

    Google Scholar 

  • Gaitz CM, Varner RV, Overall JE (1977) Pharmacotherapy for organic brain syndrome in late life. Evaluation of an ergot derivative vs placebo. Arch Gen Psychiatry 34: 839–845

    Article  PubMed  CAS  Google Scholar 

  • Gherondache DN (1977) Data on file at Sandoz Inc, East Hanover, NJ, USA

    Google Scholar 

  • Goldstein M (1985) Ergot alkaloids and central monoaminergic receptors. J Pharmacol (Paris) 16 [Suppl III]: 19–24

    Google Scholar 

  • Goldstien M, Lew JY, Hata F, Lieberman A (1978) Binding interactions of ergot alkaloids with monoaminergic receptors in the brain. Gerontology 24 [Suppl I] 76–85

    Article  Google Scholar 

  • Gomez E (1977) Clinical observations in the treatment of tardive dyskinesia with dihydrogenated ergot alkaloids (Hydergine). Preliminary findings. Psychiat J Univ Ottawa 2: 67–71

    Google Scholar 

  • Grabner W, Weidinger G (1982) Behandlung der Hypertonie im Alter. Med Klin 77: 694–698

    Google Scholar 

  • Grauwiler J, Schoen H (1973) Teratological experiments with ergotamine in mice, rats and rabbits. Teratology 7: 227–235

    Article  PubMed  CAS  Google Scholar 

  • Griffith RW, Grauwiler J, Hodel C, Leist KH, Matter B (1978) Ergot alkaloids and related compounds. In: Berde B, Schild HO (eds) Handbuch der experimentellen Pharmakologie, vol 49. Springer, Berlin Heidelberg New York, pp 805–851

    Google Scholar 

  • Guffanti E, Vaccarella A, Meregalli M, Fiorella G, Chierichetti SM, Mazzola C (1985) A single blind comparison of dihydroegotoxine mesilate and clonidine for treatment of hypertensive emergencies. Int J Clin Pharmacol Ther Toxicol 23: 506–509

    PubMed  CAS  Google Scholar 

  • Guiraud-Chaumeil B, Rascol A, David J, Boned B, Clanet M, Bierme R (1982) Prevention des recidives des accidents vasculaires cerebraux ischemiques par les anti-agregants plaquettaires. Rev Neurol (Paris) 138: 367–385

    CAS  Google Scholar 

  • Gygax P, Meier-Ruge W, Schulz U, Enz A (1976) Proceedings: experimental studies on the action of metabolic and vasoactive substances in the oligemically disturbed brain. Arzneimittelforschung 26: 1245–1246

    PubMed  CAS  Google Scholar 

  • Hajioff J, Wallace MG (1982) Treatment of tardive dyskinesia with Co-Dergocrine mesylate. Br J Clin Pract 16: 43–46

    Google Scholar 

  • Heiss R, Seus R, Fahrenberg J (1971) Eine Studie zur Prüfung der psychodynamischen Wirkung von Dihydroergotoxin. Arzneimittelforschung 21: 797–800

    PubMed  CAS  Google Scholar 

  • Herzfeld U, Christian W, Oswald WD et al. (1972) Zur Wirkungsanalyse von Hydergin im Langzeitversuch. Eine interdisziplinäre Studie. Med Klin 67: 1118–1125

    PubMed  CAS  Google Scholar 

  • Heuer LJ, Anders T (1983) Behandlung der Hochdruckkrise mit Hydergin. Med Klin 78: 564–566

    Google Scholar 

  • Hollingsworth SW (1974) Effective nursing home care for elderly patients. Evaluation and treatment. Scient Exhibit Am Med Assoc Clin Convention, Portland, Oregon

    Google Scholar 

  • Hollingsworth SW (1980) Response of geriatric patients from the satellite nursing homes of Maricopa County to Hydergine therapy: a double-blind study. Curr Ther Res 27: 401–410

    Google Scholar 

  • Horowski R, Mc Donald RJ (1983) Experimental and clinical aspects of ergot derivatives used in the treatment of age-related disorders. In: Agnoli A, Crepaldi G, Spano PF, Trabucchi M (eds) Aging brain and ergot alkaloids. Raven Press, New York, pp 283–303 (Aging, vol 23)

    Google Scholar 

  • Horsch A (1982) Prüfung der blutdrucksenkenden Wirkung von Hydergin speziell unter stationären Bedingungen. Therapiewoche 32: 3882–3886

    Google Scholar 

  • Huber F, Köberle S, Prestele H, Spiegel R (1986) Effects of long-term ergoloid mesylates (“Hydergine”) administration in healthy pensioniers: 5-year results. Curr Med Res Opin 10: 256–279

    Article  PubMed  CAS  Google Scholar 

  • Hughes JR, Williams JG, Currier RA (1976) An ergot alkaloid preparation (Hydergine) in the treatment of dementia: critical review of the clinical literature. J Am Geriatr Soc 24: 490–497

    PubMed  CAS  Google Scholar 

  • Humbert H, Lavene D, Guillaume MF, Kiechel JR (1975) Pharmacokinetics and bioavailability with two ergot peptide alkaloids: co-dergocrine and dihydroergotamine. In: Gershon S, Raskin A (eds) Genesis and treatment of psychologic disorders in the elderly. Raven Press, New York, pp 334–340 (Aging, vol 2)

    Google Scholar 

  • Humbert H, Lavène D, Guillaume MF, Kiechel JK (1981) In: Aiache JM, Hirtz J (eds) 1er Congrés Européen de Biopharmacie et de Pharmacocinétique. Technique et Documentation, Paris, vol 1, pp 334–340

    CAS  Google Scholar 

  • Hunziker O, Emmenegger H, Meier-Ruge W, Schulz U (1974) The behaviour of morphometric parameters of cortical capillaries in the cat’s brain influenced by DH-ergotoxine and papaverine. Int Res Commun Syst Med Sci 2: 1481–1489

    CAS  Google Scholar 

  • Iwangoff P, Enz A, Chappuis A (1975) Inhibition of cAMP-phosphodiesterase of different cat organs by DH-ergotoxine in the micromolar substrate range. Int Res Commun Syst Med Sci 3: 403–406

    CAS  Google Scholar 

  • Iwangoff P, Meier-Ruge W, Schieweck C, Enz A (1976) The uptake of DH-ergotoxine by different parts of the cat brain. Pharmacology 14: 27–38

    Article  PubMed  CAS  Google Scholar 

  • Jennings WC (1972) An ergot alkaloid preparation (Hydergine) versus placebo for treatment of symptoms of cerebrovascular insufficiency: double-blind study. J Am Geriatr Soc 20: 407–412

    PubMed  CAS  Google Scholar 

  • Kappert A, Baumgartner P, Rupp F (1948) Über die blutdmcksenkende Wirkung neuer hydrierter Mutterkornalkaloide. Schweiz Med Wochenschr 78: 1265

    PubMed  CAS  Google Scholar 

  • Kawashima K, Kogure K, Ido T, Itoh M, Hatazawa J (1988) Increase in cerebral metabolic rate of glucose in multi-infarct dementia following intravenous administration of codergocrine mesylate (Hydergine). Neurol 235 [Suppl]: 1

    Article  Google Scholar 

  • Koeberle S, Spiegel R (1984) A long-term study with Co-Dergocrine mesylate (Hydergine) in healthy pensioners. Result after 3 years. Gerontology 30 [Suppl 1]: 3–52

    CAS  Google Scholar 

  • Kugler J, Oswald WD, Herzfeld U et al. (1978) Langzeittherapie altersbedingter Insuffizienzerscheinungen des Gehirns. Dtsch Med Wochenschr 103: 456–462

    Article  PubMed  CAS  Google Scholar 

  • Lancranjan I (1983) New perspectives in the treatment of tardive dyskinesia with dihydroergotoxine. In: Agnoli A, Crepaldi C, Spano PF, Trabucchi M, Rom (eds) Aging brain and ergot alkaloids. Raven Press, New York, pp 329–338 (Aging, vol 23)

    Google Scholar 

  • Lavène D, Humbert H, Kiechel JR et al. (1985) Hydergine pharmacokinetics in the elderly. J Pharmacol (Paris) 16 [Suppl III]: 57–63

    Google Scholar 

  • Le Poncin-Lafitte M, Rapin JR, Duterte D (1985) Learning and cholinergic neurotransmission in old animals: the effect of Hydergine. J Pharmacol (Paris) 16 [Suppl III]: 57–63

    Google Scholar 

  • Linden ME (1975) Retirement and the elderly patient: problems and practical therapy. Scientific exhibit; 1–19 Am Geriatr Soc, 124th Annual Meeting

    Google Scholar 

  • Loew DM, Vigouret JM, Jaton AL (1976a) Neuropharmacological investigations with two ergot alkaloids, Hydergine and bromocriptine. Postgrad Med J 52 [Suppl 1]: 40–46

    PubMed  CAS  Google Scholar 

  • Loew DM, Deporteere H, Bürki HR (1976b) Effects of dihydrogenated ergot alkaloids on the sleep wakefulness cycle and on brain biogenic amines in the rat. Arzneimittelforschung 26: 1080–1083

    PubMed  CAS  Google Scholar 

  • London ED, Walovitch RC (1985) Cerebral gluco se metabolism in aging rodents: effects of codergocrine. J Pharmacol (Paris) 16 [Suppl III]: 73–84

    Google Scholar 

  • Markstein R (1985) Hydergine: interaction with neurotransmitter systems in the central nervous system. J Pharmacol (Paris) 16 [Suppl III]: 1–7

    CAS  Google Scholar 

  • Markstein R, Wagner H (1978) Effects of dihydroergotoxine on cyclic AMP generating systems in rat cerebral cortex slices. Gerontology 24 [Suppl 1]: 94–105

    Article  PubMed  CAS  Google Scholar 

  • Markstein R, Closse A, Frick W (1983) Interaction of ergot alkaloids and their combination (codergocrine) with α-adrenoceptors in the CNS. Eur J Pharmacol 93: 156–169

    Article  Google Scholar 

  • Matejcek M (1983) EEG of the aging brain. Contribution of quantitative electroencephalography to geriatric research: application with ergoloid mesylates. In: Agnoli A, Crepaldi G, Spano PF, Trabucchi M (eds) Aging brain and ergot alkaloids. Raven Press, New York, pp 97–103 (Aging, vol 23)

    Google Scholar 

  • Matejcek M, Knor K, Piguet PV, Weil C (1979) Electroencephalographic and clinical changes as correlated in geriatric patients treated three months with an ergot alkaloid preparation. J Am Geriatr Soc 27: 198–202

    PubMed  CAS  Google Scholar 

  • Mauer BE, Grauwiler J (1975) The micronucleus test as a simple model, in vivo, for the evaluation of drug — induced chromosome aberrations. Comparative studies with 13 compounds. Mutation Res 29: 198–199

    Google Scholar 

  • Matter BE, Tsuchimoto T, Deyssenroth H (1978) Failure to detect dominant — lethal mutations and effects On reproductive capacity in mice exposed to dihydroergotoxine mesylate. Arzneimittelforschung 28: 2286–2290

    PubMed  CAS  Google Scholar 

  • Mc Connachie RW (1973) A clinical trial comparing Hydergine with placebo in the treatment of cerebrovascular insufficiency in elderly patients. Curr Med Res Opin 1: 463–468

    Article  Google Scholar 

  • Mc Donald RJ (1979) Hydergine: a review of 26 clinical studies. Pharmakopsychiatry 12: 407–422

    Article  Google Scholar 

  • Meier Ruge W (1986) Effects of prolonged codergocrine mesylate (Hydergine) treatment on local cerebral glucose uptake in aged Fischer 344 rats. Arch Gerontol Geriatr 5: 65–77

    Article  PubMed  CAS  Google Scholar 

  • Meier Ruge W, Enz A, Gygax P et al. (1975) Experimental pathology in basic research of the aging brain. In: Gershon S, Raskin A (eds) Genesis and treatment of psychologic disorders in the elderly. Raven Press, New York, pp 55–126 (Aging, vol 2)

    Google Scholar 

  • Mémin Y, Najean Heuber E (1973) Etude à double insu selon une échelle d’appréciation quantitative d’un traitement des troubles vasculaires cérébraux chroniques. Semin Hôp (Paris) 49: 605–608

    Google Scholar 

  • Moglia A, Bono G, Sinforiani E, Alffonsi E, Zandrini C, Pistarini C, Arrigo A, Franch F (1983) Farmaco (ed prat) 38: 97–102

    CAS  Google Scholar 

  • Nagasawa H, Kogure K, Kawashima T et al. (1989) Influence of Hydergine on brain cell metabolism as demonstrated by Pet. In: Carlsson A, Kanowski S, Allain H, Spiegel R (eds) Cerebral insufficiency. Trends in research and treatment, vol 1–4. Parthenon Publishing Group, Carnforth (UK) and Park Ridge (USA), vol 3, pp 169–178

    Google Scholar 

  • Nelson JJ (1975) Relieving selected symptoms of the elderly. Geriatrics 30: 133–142

    PubMed  CAS  Google Scholar 

  • Orth OA, Capps RA, Suckle HM (1947) Some pharmacological properties of dihydroergocornine (DHO 180). Red Proc 6: 361

    CAS  Google Scholar 

  • Oswald WD, Lang E (1980) Therapeutische Beeinflussung von Leistung und Selbstbild bei geriatrischen Patienten. Münch Med Wochenschr 122: 59–62

    CAS  Google Scholar 

  • Oswald WD, Matejcek M, Lukaschek K (1982) Über die Relevanz psychometrisch operationalisierter Therapie-Effekte bei der Behandlung altersbedingter Insuffizienzerscheinungen des Gehirns als Beispiel des NürnbergerAlters-Inventars. Arzneimittelforschung 32: 584–590

    PubMed  CAS  Google Scholar 

  • Rao DB, Norris JR (1972) A double-blind investigation of hyclergine in the treatment of cerebrovascular insufficiency in the elderly. Johns Hopk Med J 130: 317–324

    CAS  Google Scholar 

  • Rei Iman SA (1973) Two trials comparing Hydergine with placebo in the treatment of patients suffering from cerebrovascular insufficiency. Curr Med Res Opin 1: 456–462

    Article  Google Scholar 

  • Roberts GT, Rand MJ (1977) Effects of some ergot derivates in bone marrow of mice. Mutation Res 56: 59–67

    Article  PubMed  CAS  Google Scholar 

  • Rodriguez JM (1973) A double-blind placebo controlled study of Hydergine in the treatment of cerebrovascular insufficiency in the elderly. Data on file at Sandoz Inc, East Hanover, NJ, USA

    Google Scholar 

  • Rosen HJ (1975) Mental decline in the elderly: pharmacotherapy (ergot alkaloids versus papaverine). J Am Geriatr Soc 23: 169–174

    PubMed  CAS  Google Scholar 

  • Rothlin E, Bruegger J (1945) Quantitative Untersuchungen der sympathikolytischen Wirkung genuiner Mutterkornalkaloide und derer Dihydroderivate am isolierten Uterus des Kaninchens. Helv Physiol Acta 3: 519

    CAS  Google Scholar 

  • Rothlin E, Cerletti A (1949) Pharmakologie des Hochdrucks. Verh Dtsch Ges Kreisl Forsch 15: 158

    Google Scholar 

  • Roubicek J, Geiger C, Abt K (1972) An ergot alkaloid preparation (hydergine) in geriatric therapy. J Am Geriatr Soc 20: 222–229

    PubMed  CAS  Google Scholar 

  • Rouy JM, Douillon AM, Compan B (1986) L’Hydergine dans le traitement de la détérioration intellectuelle du sujet âgé. Résultats d’un essai double insu d’une durée de 6 mois. Trib Méd 200: 69–74

    Google Scholar 

  • Salzmann R, Pacha W (1976) The effects of ergot compound on the release of noradrenaline and prostaglandins from the isolated perfused cat spleen during nerve stimulation. Postgrad Med J 52 [Suppl 1]: 24–31

    PubMed  CAS  Google Scholar 

  • Segre G, Bruni B, Dal Pra P et al. (1983) Pharmacokinetic analysis: new methods and results with ergot alkaloids. In: Agnoli A, Crepaldi G, Spano PF, Trabucchi M (eds) Aging brain and ergot alkaloids. Raven Press, New York, pp 395–406 (Aging, vol 23)

    Google Scholar 

  • Singer JM, Harnot HB, Patin JR (1985) Differential patient response to ergoloid mesylates according to current etiopathic notions of dementia. In: Gaitz CM, Samorajski T (eds) Aging 2000: our health care destiny. Springer, New York, pp 405–420 (Biochemical issues, vol 1)

    Chapter  Google Scholar 

  • Smith JA, Zalman S (1949) Prac Soc Ep Biol (NY) 72: 13–15

    Article  CAS  Google Scholar 

  • Sörgel F, Abisch E, Dennler HJ, Lang E (1984) Steady state bioavailability of a new oral formulation of Hydergine in geriatric patients. Eur Clin Pharmacol 26: 133–135

    Article  Google Scholar 

  • Susic V, Masirevic G (1979) Effects of dihydroergotoxine (Hydergine) on the sleep-wakefulness cycle the cat. Gerontology 25: 212–218

    Article  PubMed  CAS  Google Scholar 

  • Thibault A (1974) A double-blind evaluation of “Hydergine” and placebo in the treatment of patients with organic brain syndrome and cerebral arteriosclerosis in a nursing home. Curr Med Res Opin 2: 482–487

    Article  PubMed  CAS  Google Scholar 

  • Thienhaus OJ, Wheeler BG, Simons S et al. (1987) A controlled double-blind study of high-dose dihydroergotoxine mesylate (Hydergine) in mild dementia. J Am Geriatr Soc 35: 219–223

    PubMed  CAS  Google Scholar 

  • Triboletti F, Ferri H (1969) Hydergine for treatment of symptoms of cerebrovascular insufficiency. Curr Ther Res 11: 609–620

    PubMed  CAS  Google Scholar 

  • Venn RD (1978) Clinical pharmacology of ergot alkaloids in senile cerebral insufficiency. In: Berde B, Schild HO (eds) Ergot alkaloids and related compounds. Springer, Berlin Heidelberg New York, pp 533–566 (Handbook Exp Pharmacol, vol 49)

    Chapter  Google Scholar 

  • Vigouret JM, Brürki HR, Jaton AL et al. (1978) Neurochemical and neuropharmacological investigations with four ergot derivatives: bromocriptine, dihydroergotoxine, CF 25–397 and CM 29–712. Pharmacology 16 [Suppl 1]: 156–173

    Article  PubMed  CAS  Google Scholar 

  • Weil C (1988) Hydergine: pharmacologic and clinic facts. Springer, Berlin Heidelberg New York Tokyo

    Book  Google Scholar 

  • Wennmalm A (1971) Quantitative evaluation of release and reuptake of adrenergic transmitter in the rabbit heart. Acta Physiol Scand 82: 532–538

    Article  PubMed  CAS  Google Scholar 

  • Weth G (1982) Zur Behandlung der hypertonen Krise mit Hydergin. Z Allg Med 58: 1366–1368

    CAS  Google Scholar 

  • Wiernsperger N, Gygax P, Danzeisen M (1978) Cortical po-distribution during oligemic hypotension and its pharmacological modifications. Arzneimittelforschung 28: 768–770

    PubMed  CAS  Google Scholar 

  • Wilder BJ, Gonyea EF (1973) The effects of the dihydrogenated ergot alkaloids on symptoms of aging: a controlled pilot study of clinical neurologic and EEG changes. Scientific exhibit. Am Med Ass Annu Convention, New York, June 23–27

    Google Scholar 

  • Winslow IE (1974) The hospitalized geriatric patient: guidelines for effective therapy. Scientific exhibit: 1–24. Am Med Assoc Meeting, Portland, Nov 30–Dec 3

    Google Scholar 

  • Wright AM, Morrehead M, Welsh JH (1962) Br J Pharmacol 18: 440–450

    CAS  Google Scholar 

  • Yesavage JA, Tinklenberg JR, Hollister LE, Berger PA (1979) Vasodilators in senile dementias: a review of the literature. Arch Gen Psychiatry 36: 220–223

    Article  PubMed  CAS  Google Scholar 

  • Yesavage JA, Westphal J, Rush L (1981) Senile dementia: combined pharmacologic and psychologic treatment. J Am Geriatr Soc 29: 164–174

    PubMed  CAS  Google Scholar 

  • Zuger PE, Vigouret JM, Loew DM (1978) Inhibition of reserpine-induced PGO-spikes in the cat by ergot derivatives. Experientia 34: 637–639

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. H. Herrschaft
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrische Universitätsklinik, Würzburg, Bundesrepublik Deutschland

    Peter Riederer

  2. Psychiatrische Universitätsklinik, Bonn, Bundesrepublik Deutschland

    Gerd Laux

  3. Psychiatrische Universitätsklinik, Basel, Schweiz

    Walter Pöldinger

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag Wien

About this chapter

Cite this chapter

Herrschaft, H. (1992). Co-Dergocrin (Dihydroergotoxin). In: Riederer, P., Laux, G., Pöldinger, W. (eds) Neuro-Psychopharmaka. Springer, Vienna. https://doi.org/10.1007/978-3-7091-3330-9_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-3330-9_15

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-3331-6

  • Online ISBN: 978-3-7091-3330-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation